BEDFORD, Mass.--(BUSINESS WIRE)--Jan. 11, 2016--
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced the appointment
of Jonathan H. Talamo, M.D. to the position of Chief Medical Officer. In
this role, Dr. Talamo will help advance Ocular’s development pipeline,
including lead therapeutic candidate, DEXTENZATM.
“Jonathan brings a wealth of expertise to Ocular during an exciting time
in our Company’s growth, and we are excited to welcome him to the team,”
said Dr. Amar Sawhney, Ph.D., President, Chief Executive Officer and
Chairman of Ocular. “Since the acceptance by the FDA of our NDA
submission of DEXTENZA for the treatment of post-surgical ocular pain in
the fourth quarter of 2015, we have been preparing for its potential
commercialization, as well as advancing the DEXTENZA platform in
allergic conjunctivitis and dry eye and OTX-TP for glaucoma. Jonathan is
an internationally-known and well regarded ophthalmologist whose
experience as a practicing ophthalmic surgeon, coupled with his
scientific advisory roles for numerous prominent ophthalmology
companies, will be valuable as we continue to advance through the
clinical and regulatory process.”
Dr. Talamo joins Ocular with more than 25 years of industry experience
as an ophthalmologist, innovator and industry consultant. Dr. Talamo has
advised many early to late stage ophthalmology companies such as
Alcon/Novartis, Allergan, Bausch & Lomb, Shire, as well as Ocular, in
the areas of product R&D, clinical trial design, regulatory issues,
business development strategy, fund raising and marketing. He was an
investigator for many of the early clinical trials that led to FDA
approval of lasers for vision correction with PRK and LASIK as well as
image guided lasers for refractive cataract surgery. Dr. Talamo
currently serves as an Associate Professor of Ophthalmology at Harvard
Medical School and as Director of the Massachusetts Eye and Ear
Infirmary (MEEI) Waltham, a Harvard-affiliated teaching hospital. Dr.
Talamo is also Chairman of the Program Committee and on the Executive
Board of the New England Ophthalmological Society. He was a recipient of
Honor and Senior Achievement awards from the American Academy of
Ophthalmology for his clinical research and teaching expertise. Dr.
Talamo received his M.D. degree from The Johns Hopkins University School
of Medicine and completed an ophthalmology residency at the Wilmer
Ophthalmological Institute of The Johns Hopkins Hospital. Dr. Talamo
completed a clinical fellowship in cornea and external disease at
Massachusetts Eye and Ear Infirmary.
“I believe Ocular has tremendous potential and am thrilled to be joining
at a time when the pipeline consists of several mid and late-stage
clinical programs,” said Dr. Talamo. “I look forward to helping to
advance its proprietary hydrogel technology for patients who can benefit
from sustained-release therapies."
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidate, DEXTENZA™, is in Phase 3 clinical development for post-surgical ocular inflammation and pain and allergic conjunctivitis, and in Phase 2 clinical development for inflammatory dry eye disease. An NDA for the post-operative ocular pain indication has been accepted by the FDA with a PDUFA date of July 24, 2016. A third Phase 3 clinical trial is being conducted for post-operative ocular inflammation and pain. For glaucoma and ocular hypertension, OTX-TP (sustained release travoprost) intracanalicular depot, has completed a Phase 2b clinical trial. Ocular Therapeutix is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.
Forward Looking Statements
Any statements in this press release about future expectations, plans
and prospects for the Company, including statements about the
advancement, development or potential launch and commercialization of
the Company’s product candidates, the potential for the Company’s
sustained release hydrogel depot technology, the Company’s plans for or
success with regulatory submissions, and other statements containing the
words "anticipate," "believe," "estimate," "expect," "intend", "goal,"
"may", "might," "plan," "predict," "project," "target," "potential,"
"will," "would," "could," "should," "continue," and similar expressions,
constitute forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors. Such forward-looking statements
involve substantial risks and uncertainties that could cause the
Company’s clinical development programs, future results, performance or
achievements to differ significantly from those expressed or implied by
the forward-looking statements. Such risks and uncertainties include,
among others, those related to the timing and costs involved in
commercializing ReSure® Sealant, the initiation and conduct of clinical
trials, availability of data from clinical trials and expectations for
regulatory submissions and approvals, the Company’s scientific approach
and general development progress, the availability or commercial
potential of the Company’s product candidates, the sufficiency of cash
resources and need for additional financing or other actions and other
factors discussed in the “Risk Factors” section contained in the
Company’s quarterly and annual reports on file with the Securities and
Exchange Commission. In addition, the forward-looking statements
included in this press release represent the Company’s views as of the
date of this release. The Company anticipates that subsequent events and
developments will cause the Company’s views to change. However, while
the Company may elect to update these forward-looking statements at some
point in the future, the Company specifically disclaims any obligation
to do so. These forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the date
of this release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160111005423/en/
Source: Ocular Therapeutix, Inc.
Investors:
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
bsmith@ocutx.com
or
Burns
McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich,
212-213-0006
kminarovich@burnsmc.com
or
Media:
Scott
Corning
Vice President of Sales and Marketing
scorning@ocutx.com
